ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical practice"

  • Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium

    Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Mei-Sing Ong1, Gordon Schiff 2 and Marc Natter 3 for the CARRA investigators, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Harvard Medical School, Boston, 3Boston Children's Hospital, Boston

    Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…
  • Abstract Number: 191 • 2020 Pediatric Rheumatology Symposium

    Utilization of Telemedicine in Pediatric Rheumatologic Care

    Rajdeep Pooni1 and Tzielan Lee 1, 1Stanford Children's, Palo Alto

    Background/Purpose: Telemedicine has the potential for improving access to care, particularly for pediatric patients with complex needs in remote or rural locations. Previous studies have…
  • Abstract Number: 302 • 2019 ACR/ARP Annual Meeting

    Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center

    Sarah Chung1, Katherine Wysham 2, Elizabeth Jernberg 3, Ingeborg Sacksen 3, Scott Pollock 1 and Alison Bays 1, 1University of Washington Division of Rheumatology, Seattle, WA, 2Veterans Health Administration Puget Sound, Seattle WA, Seattle, 3University of Washington Division of Rheumatology, Seattle

    Background/Purpose: Routine use of musculoskeletal ultrasound (MSK-US) to aid in clinical decision-making for rheumatology patients is less common in the United States than in Europe,…
  • Abstract Number: 654 • 2019 ACR/ARP Annual Meeting

    Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease

    Kyle Drehmel1, Alan Erickson 1, Bryant England 2 and Michelene Hearth-Holmes 1, 1University of Nebraska Medical Center, Omaha, NE, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha

    Background/Purpose: Undifferentiated Connective Tissue Disease (UCTD) describes the clinical scenario where a patient demonstrates characteristics of a connective tissue disease but does not meet criteria…
  • Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting

    Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe

    Uta Kiltz 1, Elizabeth Holdsworth2, Haijun Tian 3, Nicola Booth 4, Papa Anthony 5, Lina Helsche 6, Dorothy Keininger 6 and Philip G Conaghan 7, 1Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 2Adelphi Real World, Manchester, England, United Kingdom, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Adelphi Real World, Bollington, United Kingdom, 5Adelphi Real World, Macclesfield, England, United Kingdom, 6Novartis Pharma AG, Basel, Basel-Landschaft, Switzerland, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life.  Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…
  • Abstract Number: 2461 • 2019 ACR/ARP Annual Meeting

    Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement

    Alfred Cividino1, Denise Nicholson 2, Sherif Guindi 2, Jennifer Jelley 2, Anne-Julie Gaudreau 2 and Dafna Gladman 3, 1McMaster University's Faculty of Health Sciences, Hamilton, ON, Canada, 2Celgene Corporation, Summit, NJ, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: Oligoarticular disease in patients with psoriatic arthritis (PsA) is often underdiagnosed and undertreated. The goal of this study is to understand and identify current…
  • Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting

    24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States

    Christopher Collins 1, Gail Kerr 2, Joan Von Feldt 3, Bernie Rubin 4, Arie Katz 3, Vanessa Castellano 5, Jake Chung 4 and Christopher Bell5, 1MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, 2Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC, 3GSK, Philadelphia, PA, 4GSK, Phildelphia, PA, 5GSK, Research Triangle Park, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…
  • Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting

    Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

    Rebecca Overbury1, John Bohnsack 2, CJ Inman 3, Sara Stern 3, Karen James 3, Daniel Clegg 3, Tracy Frech 4 and Aimee Hersh 3, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2University of Utah School of Medicine, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT, 4Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT

    Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
  • Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting

    The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort

    Adel Andemeskel1, Vivi Feathers 1, Christine Iannaccone 1, Jing Cui 1 and Nancy Shadick 1, 1Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…
  • Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting

    Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice

    Dalifer Freites Núñez1, Zulema Rosales Rosado1,2, Judit Font Urgelles2, Isabel Hernández-Rodríguez2, Leticia Leon1, Gloria Candelas Rodriguez2, Luis Rodriguez-Rodriguez1, Benjamín Fernández-Gutiérrez1,2, Juan A Jover Jover2 and Lydia A Alcazar1, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…
  • Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting

    Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE

    Rebecca Heijke1, Mathilda Björk1, Martina Frodlund1, Laura McDonald2, Evo Alemao3 and Christopher Sjöwall1, 1Linköping University, Linköping, Sweden, 2Bristol-Myers Squibb, Uxbridge, United Kingdom, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
  • Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice

    Monica Calderón Goercke1, Javier Loricera2, Diana Prieto Peña1, Vicente Aldasoro3, Santos Castañeda4, Ignacio Villa-Blanco5, Alicia Humbría6, Clara Moriano Morales7, Susana Romero-Yuste8, Francisco Javier Narváez9, Catalina Gómez-Arango10, Eva Perez Pampín11, Rafael Melero12, Elena Becerra-Fernández13, Marcelino Revenga Martínez14, Noelia Álvarez-Rivas15, Carlos Galisteo16, Francisca Sivera17, Alejandro Olivé-Marqués18, Maria Concepcion Alvarez de Buergo19, Luisa Marena Rojas Vargas20, Carlos Fernandez-Lopez21, Francisco Navarro22, Enrique Raya Álvarez23, Eva Galindez-Agirregoikoa24, Beatriz Arca25, Roser Solans26, Arantxa Conesa27, Cristina Hidalgo-Calleja28, Carlos Vázquez29, Francisco Ortiz-Sanjuán30, Pau Lluch31, Sara Manrique-Arija32, Paloma Vela33, Eugenio De Miguel34, Carmen Torres-Martín35, Juan Carlos Nieto36, Carmen Ordas-Calvo37, Eva Salgado-Pérez38, María Varela-García39, Cristina Luna Gómez40, Francisco J. Toyos Sáenz de Miera41, Nagore Fernandez-Llanio Cornella42, Jose Andrés Román Ivorra43, Antonio García44, Natalia Palmou-Fontana45, Vanesa Calvo-Río45, José Luis Martín-Varillas45, Belén Atienza-Mateo45, Carmen González-Vela46, Alfonso Corrales45, Elena Aurrecoechea47, Raquel Dos Santos48, Angel García-Manzanares13, Norberto Ortego Centeno49, Sabela Fernández50, Montserrat Corteguera35, Miguel Angel González-Gay2, José Luis Hernández2 and Ricardo Blanco45, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 4Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, 7Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 8Hospital de Pontevedra. Spain, Pontevedra, Spain, 9Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 10Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 11Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 12Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 13Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, 14Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 15Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 16Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, 17Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 18Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 19Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 20Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 21Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, 22Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, 23Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 24Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, 25Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 26Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 27Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 28Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, 29Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, 31Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, 32Medicine, University of Málaga, MÁLAGA, Spain, 33Reumatología, Hospital General Universitario Alicante, Alicante, Spain, 34Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 35Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, 36Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 37Hospital Cabueñes, Gijón. Spain, Gijón, Spain, 38Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, 39Complejo Hospitalario de Navarra, Navarra, Spain, 40Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, 41Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 42Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 43Hospital La Fe. Valencia. Spain, Valencia, Spain, 44Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, 45Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 46Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 47Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 48Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, 49Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 50Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain

    Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…
  • Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting

    A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial

    Monica Calderón Goercke1, Javier Loricera2, Diana Prieto Peña1, Vicente Aldasoro3, Santos Castañeda4, Ignacio Villa-Blanco5, Alicia Humbría6, Clara Moriano Morales7, Susana Romero-Yuste8, Francisco Javier Narváez9, Catalina Gómez-Arango10, Eva Perez Pampín11, Rafael Melero12, Elena Becerra-Fernández13, Marcelino Revenga Martínez14, Noelia Álvarez-Rivas15, Carlos Galisteo16, Francisca Sivera17, Alejandro Olivé-Marqués18, Maria Concepcion Alvarez de Buergo19, Luisa Marena Rojas Vargas20, Carlos Fernandez-Lopez21, Francisco Navarro22, Enrique Raya Álvarez23, Eva Galindez-Agirregoikoa24, Beatriz Arca25, Roser Solans26, Arantxa Conesa27, Cristina Hidalgo-Calleja28, Carlos Vázquez29, Jose Andrés Román Ivorra30, Pau Lluch31, Sara Manrique-Arija32, Paloma Vela33, Eugenio De Miguel34, Carmen Torres-Martín35, Juan Carlos Nieto36, Carmen Ordas-Calvo37, Eva Salgado-Pérez38, Cristina Luna Gómez39, Francisco J. Toyos Sáenz de Miera40, Nagore Fernandez-Llanio Cornella41, Antonio García42, Carmen Larena43, Belén Atienza-Mateo44, José Luis Martín-Varillas44, Natalia Palmou-Fontana2, Vanesa Calvo-Río44, Carmen González-Vela45, Alfonso Corrales44, María Varela-García46, Elena Aurrecoechea47, Raquel Dos Santos48, Angel García-Manzanares13, Norberto Ortego Centeno49, Sabela Fernández50, Francisco Ortiz-Sanjuán51, Montserrat Corteguera35, Miguel Angel González-Gay2, José Luis Hernández2 and Ricardo Blanco44, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 4Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, 7Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 8Hospital Pontevedra. Pontevedra. Spain., Pontevedra, Spain, 9Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, 10Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 11Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 12Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 13Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, 14Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 15Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 16Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, 17Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 18Hospital Trías i Pujol, Badalona, Barcelona, Spain, 19Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 20Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 21Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, 22Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, 23Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 24Rheumatology, University Hospital of Basurto, Bilbao, Spain, 25Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 26Systemic Autoimmune Diseases Unit, Hospital Vall d’Hebron, Barcelona, Barcelona, Spain, 27Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 28Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, 29Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, 30Hospital La Fe. Valencia. Spain, Valencia, Spain, 31Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, 32UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain., Málaga, Spain, 33Reumatología, Hospital General Universitario Alicante, Alicante, Spain, 34Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 35Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, 36Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 37Hospital Cabueñes, Gijón. Spain, Gijón, Spain, 38Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, 39Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, 40Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 41Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 42Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, 43Hospital General Universitario Gregorio Marañón, Madrid, Spain, 44Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 45Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 46Complejo Hospitalario de Navarra, Navarra, Spain, 47Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 48Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, 49Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 50Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 51Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain

    Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
  • Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting

    Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

    Sebastian H. Unizony1, Jinglan Pei2, Páris N. Sidiropoulos2, Jennie H. Best2, Christine Birchwood2 and John H. Stone3, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, CA, 3Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
  • Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting

    Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice

    Judit Font Urgelles1, Luis Rodriguez-Rodriguez2, Zulema Rosales Rosado1,2, Dalifer Freites Núñez2, Leticia Leon2, Inmaculada Morado1, Esperanza Pato Cour1, Juan A Jover Jover1, Benjamín Fernández-Gutiérrez1 and Lydia A Alcazar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology